SELLAS Life Sciences Group Inc., a biopharmaceutical firm that innovates novel cancer immunotherapies, has recently revealed the enrollment of initial patient in investigator-sponsored clinical study of GPS (Galinpepimut-S), its WT1 (Wilms tumor-1)-targeting peptide immunotherapeutic agent, in combination with nivolumab (Opdivo®), for patients suffering from MPM (Malignant Pleural Mesothelioma). As per reports, the study focuses on exploring the potential of GPS with nivolumab to establish meaningful clinical activity in the presence of macroscopic disease and anti-tumor immune responses in patients suffering from MPM. The study also focuses on assessing the degree of clinical benefit by evaluation of the whole response rate in mixture with nivolumab when compared to nivolumab’s sole results. Speaking on the development, Angelos Stergiou, MD, ScD h.c., Chief Executive Officer and President, SELLAS, said that the company is delighted to partner with Memorial Sloan Kettering and is thrilled to further its Phase 1 trial that focuses on expanding the evaluation of GPS when combined with nivolumab in patients suffering from advanced MPM. Stergiou added that the combined therapy could be effective for crucial anti-tumor activity and the company is looking forward to attaining deep insights on the clinical outcomes and safety of this trial. Reportedly, the development comes on heels of recent management change in SELLAS. The company recently appointed Dragan Cicic, MD, as its clinical development’s senior vice president. Reports claim that Dr. Cicic would undertake the responsibilities of clinical development and will directly report to Angelos Stergiou. Commenting on which, Stergiou said that SELLAS is pleased to welcome Dr. Cicic in its family and is looking forward to adding his vast experience and expertise to their firm. Dr. Cicic’s in-depth knowledge and experience about both clinical development area and hematology-oncology drug candidates could benefit SELLAS’ ongoing clinical activity for its GPS program, added Stergiou. Source Credit: